Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036177 | 0.98 | MEN1 (0.61) | KDM2BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL1039910 | 0.98 | MEN1 (0.61) | KDM2BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL9136904 | 0.83 | NPC1 (0.77) | KDM2BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL18360283 | 0.82 | KDM2B (0.62) | KDM2BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL9135757 | 0.81 | NPC1 (0.75) | KDM2BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL4611341 | 0.81 | NPC1 (0.75) | KDM2BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL16106340 | 0.80 | NPC1 (0.54) | KDM2BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL5270856 | 0.80 | MAPK1 (0.73) | KDM2BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL3367257 | 0.79 | NPC1 (0.77) | KDM2BKMT2AMEN1NPC1RAB9A | |
| SCHEMBL23734465 | 0.79 | SIRT5 (0.58) | KMT2AMEN1NPC1RAB9APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102348674-A | Leukotriene b4 inhibitors | HOFFMANN LA ROCHE | 2012-02-08 | — | — | CN | disclosed |
| EP-2411358-A1 | LEUKOTRIENE B4 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2012-02-01 | — | — | EP | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-8088936-B2 | Leukotriene B4 inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-1633733-B1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | UNIV TENNESSEE RES FOUNDATION (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-2010108856-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010108856-A1 | LEUKOTRIENE B4 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | DOMINIQUE ROMYR | 2010-09-23 | — | — | US | disclosed |
| US-20070167514-A1 | Cannabinoid derivatives, methods of making, and use thereof | UNIVERSTIY OF TENNESSEE RESEARCH FOUNDATION | 2007-07-19 | — | — | US | disclosed |
| EP-1633733-A4 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | UNIV TENNESSEE RES CORP (US) | 2007-02-28 | — | — | EP | disclosed |
| US-7169942-B2 | agonists or antagonists; treatment for neuroinflammatory pathologies involving demyelinization, viral encephalitis, cerebrovascular accidents, cranial trauma, ocular disorders, pulmonary disorders, allergic diseases, inflammatory conditions, immune system disorders, central nervous system diseases, etc. | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2007-01-30 | — | — | US | disclosed |
| EP-1633733-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004113320-A1 | CANNABINOID DERIVATIVES, METHODS OF MAKING, AND USE THEREOF | THE UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2004-12-29 | — | — | WO | disclosed |
| US-20040242593-A1 | Cannabinoid derivatives, methods of making, and use thereof | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240678-A1 | LEUKOTRIENE B4 INHIBITORS | LTB4R2, LTB4R, LTC4S | KDM2B 2247/4885KMT2A 4432/4885MEN1 4324/4885 |
| US-20040242593-A1 | Cannabinoid derivatives, methods of making, and use thereof | CNR2, CNR1, GPR18 | KDM2B 2727/4885KMT2A 1891/4885MEN1 3863/4885 |
| US-20070167514-A1 | Cannabinoid derivatives, methods of making, and use thereof | CNR2, CNR1, GPR18 | KDM2B 2772/4885KMT2A 1922/4885MEN1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.